348 related articles for article (PubMed ID: 16645972)
1. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
Suissa S; Hudson M; Ernst P
Arthritis Rheum; 2006 May; 54(5):1435-9. PubMed ID: 16645972
[TBL] [Abstract][Full Text] [Related]
2. Antirheumatic drug use and the risk of acute myocardial infarction.
Suissa S; Bernatsky S; Hudson M
Arthritis Rheum; 2006 Aug; 55(4):531-6. PubMed ID: 16874796
[TBL] [Abstract][Full Text] [Related]
3. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.
Sawada T; Inokuma S; Sato T; Otsuka T; Saeki Y; Takeuchi T; Matsuda T; Takemura T; Sagawa A;
Rheumatology (Oxford); 2009 Sep; 48(9):1069-72. PubMed ID: 19321513
[TBL] [Abstract][Full Text] [Related]
4. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis.
Bernatsky S; Hudson M; Suissa S
Rheumatology (Oxford); 2005 May; 44(5):677-80. PubMed ID: 15784627
[TBL] [Abstract][Full Text] [Related]
5. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
6. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
Wolfe F; Michaud K; Stephenson B; Doyle J
J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide-associated infections in rheumatoid arthritis.
Jenks KA; Stamp LK; O'Donnell JL; Savage RL; Chapman PT
J Rheumatol; 2007 Nov; 34(11):2201-3. PubMed ID: 17937473
[TBL] [Abstract][Full Text] [Related]
8. The risk of hospitalized infection in patients with rheumatoid arthritis.
Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
J Rheumatol; 2008 Mar; 35(3):387-93. PubMed ID: 18260176
[TBL] [Abstract][Full Text] [Related]
9. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
[TBL] [Abstract][Full Text] [Related]
10. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.
Ju JH; Kim SI; Lee JH; Lee SI; Yoo WH; Choe JY; Chung SH; Lee J; Lee YH; Lee SS; Yoon HJ; Yoon CH; Kim HY; Park SH
Arthritis Rheum; 2007 Jun; 56(6):2094-6. PubMed ID: 17530652
[No Abstract] [Full Text] [Related]
11. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
13. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.
Suissa S; Ernst P; Hudson M; Bitton A; Kezouh A
Am J Med; 2004 Jul; 117(2):87-92. PubMed ID: 15234643
[TBL] [Abstract][Full Text] [Related]
14. Antirheumatic drugs and the risk of tuberculosis.
Brassard P; Kezouh A; Suissa S
Clin Infect Dis; 2006 Sep; 43(6):717-22. PubMed ID: 16912945
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease.
Wolfe F; Caplan L; Michaud K
Scand J Rheumatol; 2007; 36(3):172-8. PubMed ID: 17657669
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified?
Rajakulendran S; Gadsby K; Deighton C
Musculoskeletal Care; 2008 Dec; 6(4):233-45. PubMed ID: 18702106
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.
Brassard P; Lowe AM; Bernatsky S; Kezouh A; Suissa S
Arthritis Rheum; 2009 Mar; 61(3):300-4. PubMed ID: 19248128
[TBL] [Abstract][Full Text] [Related]
18. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
Wolfe F; Caplan L; Michaud K
Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
[TBL] [Abstract][Full Text] [Related]
19. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide-associated pancytopenia with or without methotrexate.
Chan J; Sanders DC; Du L; Pillans PI
Ann Pharmacother; 2004; 38(7-8):1206-11. PubMed ID: 15187208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
